Futura Medical plc (AIM:FUM)

London flag London · Delayed Price · Currency is GBP · Price in GBX
1.300
-0.025 (-1.89%)
Apr 28, 2026, 4:35 PM GMT
-85.95%
Market Cap 7.56M
Revenue (ttm) 7.93M
Net Income (ttm) -6.29M
Shares Out 581.33M
EPS (ttm) -0.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,939,970
Average Volume 4,681,237
Open 1.500
Previous Close 1.325
Day's Range 1.204 - 1.500
52-Week Range 0.989 - 15.000
Beta 0.19
RSI 55.34
Earnings Date Apr 29, 2026

About Futura Medical

Futura Medical plc research, develops, and commercializes pharmaceutical and healthcare products for sexual health. The company’s lead product includes Eroxon, a topical gel for the treatment of erectile dysfunction. It also develops WSD4000 for the treatment of sexual dysfunction in women. The company operates in the United Kingdom, the European Union, the United States, and internationally. Futura Medical plc was incorporated in 2001 and is headquartered in Guildford, the United Kingdom. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 14
Stock Exchange London Stock Exchange AIM
Ticker Symbol FUM
Full Company Profile

Financial Performance

Financial Statements

News

Futura Medical Earnings Call Transcript: H1 2025

H1 2025 saw disappointing repeat sales and revenue, leading to a significant downgrade in full-year expectations and a strategic review. Cash runway extends into January 2026, with new product launches and financing options under active consideration.

7 months ago - Transcripts

Futura Medical Earnings Call Transcript: H2 2024

Achieved first profit in 2024 with GBP 14 million revenue and 70% gross margin, driven by Eroxon launches in 15+ countries. Pipeline products advancing, but sales guidance revised lower due to early-stage market dynamics and product effectiveness in younger men.

1 year ago - Transcripts

Futura Medical Earnings Call Transcript: H1 2024

Reported first-ever profit and over 300% revenue growth in H1 2024, driven by Eroxon’s rollout in 10+ countries and upcoming U.S. launch with Haleon. Gross margin was 44%, with significant manufacturing investments and updated guidance expected.

1 year ago - Transcripts